A recent study published in PubMed reveals that vitamin D supplementation significantly reduces the recurrence of benign paroxysmal positional vertigo (BPPV) in older adults. The double-blinded, randomized, controlled trial offers promising insights into a potential therapeutic intervention for this common cause of dizziness and balance problems.
The study, a single-center trial, involved older adults with vitamin D3 depletion who were randomized into either a treatment group (Group A) or a placebo group (Group B). The treatment group received 2000 IU of vitamin D3 for 13 weeks, followed by 1000 IU for another 13 weeks. A control group (Group C) consisted of vitamin D3 replete participants who were observed. All groups received dietary interventions for vitamin D3 and calcium.
The results indicated a substantial 87% reduction in BPPV recurrence rates in the treatment group (Group A) compared to the placebo group (Group B). Furthermore, the treatment group experienced 0.75 fewer clinical episodes per person-year compared to the placebo group. The time to first recurrence was also significantly longer in Group A. Notably, there was no statistically significant difference in recurrence rates or dizziness handicap scores between Group A and Group C.
Implications for Fall Risk and Postural Stability
BPPV-induced dizziness can significantly increase the risk of falls in older adults. The study's findings suggest that reducing BPPV episodes through vitamin D supplementation may improve postural stability and, consequently, lower the risk of falls in this population.
Future Directions
The researchers concluded that this trial provides a foundation for expanding the investigation of vitamin D as a standard of care treatment for BPPV patients in future phase IIb and III studies. These larger trials will be crucial to confirm these findings and establish optimal dosing regimens.
